Dyadic International Inc. (NASDAQ:DYAI) Sees Significant Decrease in Short Interest

Dyadic International Inc. (NASDAQ:DYAI) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 52,977 shares, a drop of 36.6% from the July 15th total of 83,534 shares. Based on an average trading volume of 212,919 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyadic International has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Dyadic International in the 2nd quarter worth about $177,000. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter valued at $190,000. Marathon Capital Management boosted its stake in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Stock Down 0.9%

Shares of DYAI traded down $0.01 during trading hours on Tuesday, reaching $0.77. The stock had a trading volume of 129,166 shares, compared to its average volume of 182,936. Dyadic International has a 12 month low of $0.65 and a 12 month high of $1.60. The company has a market capitalization of $28.17 million, a price-to-earnings ratio of -3.35 and a beta of 1.12. The firm has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $0.86. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.02 million. Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%. Equities research analysts predict that Dyadic International will post 0.13 earnings per share for the current fiscal year.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.